Risk factors for esophageal candidiasis in a large cohort of HIV-infected patients treated with nucleoside analogues

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 20, Issue 5, 2001, Pages 346-349

  Abgrall, S ^a   Charreau, I ^d   Joly, V ^b   Bloch, J ^a   Reynes, J ^c   Yeni, P ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b BICHAT HOSPITAL   (France)

^c GUI DE CHAULIAC HOSPITAL   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; NUCLEOSIDE ANALOG; RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD LEVEL; CANDIDA; CANDIDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; T LYMPHOCYTE; THRUSH;

EID: 0034751742     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960100497     Document Type: Article

References (14)

1. Hierarchical pattern of mucosal Candida infections in HIV-seropositive women
2. Natural history of HIV infection in the era of combination antiretroviral therapy
3. Prevention of symptomatic recurrences of esophageal candidiasis in AIDS patients after the first episode: A prospective open study
4. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
5. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients
6. The natural history of esophageal candidiasis after successful treatment in patients with AIDS
7. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
8. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
9. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
10. More on 'biased selection of controls for case-control analyses of cohort studies'
11. Esophageal infections: Risk factors, presentation, diagnosis, and treatment
12. Thrush and fever as measures of immunocompetence in HIV-1-infected men
13. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
14. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failures